Blue Water Vaccines Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
BWV Nasdaq 8731 https://www.bluewatervaccines.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Blue Water Vaccines Inc

Blue Water Vaccines Reports Year 2022 Financial Results and Recent Business Highlights - Mar 9th, 2023 1:30 pm
Blue Water Vaccines Appoints Seasoned Commercial Operations Leader Frank Jaeger as Senior Vice President of Marketing and Business Development - Feb 6th, 2023 3:15 pm
Blue Water Vaccines Announces Partnership with AbVacc for Joint Development of Novel Monkeypox and Marburg Vaccine Candidates - Feb 1st, 2023 2:15 pm
Blue Water Vaccines Announces Appointment of Seasoned Public Market and Private Equity Investment Leader Timothy Ramdeen to Board of Directors - Jan 17th, 2023 1:30 pm
Blue Water Vaccines to Present at Biotech Showcase 2023 During the 41st Annual J.P. Morgan Healthcare Conference Week in San Francisco - Jan 9th, 2023 1:30 pm
Blue Water Vaccines Announces Institutional Research Coverage by Two Notable Healthcare-Focused Wall Street Banks, Receives “Buy” Rating From Both - Dec 12th, 2022 1:30 pm
Blue Water Vaccines Organizes Key Opinion Leader Event to Discuss Unmet Need for Acute Otitis Media and Pneumonia Vaccine and Its Streptococcus pneumoniae Vaccine Candidate - Dec 6th, 2022 1:30 pm
Blue Water Vaccines (NASDAQ:BWV) Is In A Good Position To Deliver On Growth Plans - Dec 3rd, 2022 12:35 pm
Blue Water Vaccines to Present Update on Novel, Live Attenuated, Intranasally Delivered Streptococcus pneumoniae Vaccine to Prevent Acute Otitis Media, Pneumococcal Pneumonia, and Invasive Pneumococcal Disease at the World Vaccine & Immunotherapy Congress West Coast 2022 - Dec 1st, 2022 1:30 pm
Fred Smith Co. turns quick $24M deal for Chatham quarry - Nov 22nd, 2022 5:49 pm
Blue Water Vaccines Shares Jump After Licensing Pact For Chlamydia Vaccine Candidate - Nov 21st, 2022 3:18 pm
Blue Water Vaccines Announces Exclusive, Global License Agreement for Chlamydia Vaccine Candidate Development from The University of Texas Health San Antonio - Nov 21st, 2022 1:00 pm
Blue Water Vaccines Reports Third Quarter 2022 Financial Results and Recent Business Highlights; Announces 5 Million Share Repurchase Program - Nov 10th, 2022 1:47 pm
Blue Water Vaccines Announces Appointment of Vuk Jeremić, Previous Chair of the Council of Europe’s Committee of Ministers and Previous President of the United Nations General Assembly, to Its Board of Directors - Nov 8th, 2022 1:30 pm
Blue Water Vaccines Announces Plans to Evaluate Efficacy of Streptococcus pneumoniae Vaccine Candidate Against Pneumococcal Pneumonia at the World Vaccine Congress in Barcelona - Oct 11th, 2022 1:15 pm
Blue Water Vaccines to Present at World Vaccine Congress Europe 2022 - Sep 21st, 2022 12:00 pm
Blue Water Vaccines to Present In Person and via Webcast at H.C. Wainwright’s 24th Annual Global Investment Conference in New York, NY - Sep 8th, 2022 2:30 pm
Blue Water Vaccines to Present at H.C. Wainwright’s 24th Annual Global Investment Conference in New York, NY - Aug 31st, 2022 12:30 pm
Blue Water Vaccines to Present at The Universal Influenza Vaccines 2022 Conference in Oxford, United Kingdom - Aug 24th, 2022 6:00 pm
Blue Water Vaccines Announces Appointment of Retired Deloitte Consulting Senior Managing Director Simon Tarsh to Board of Directors - Aug 22nd, 2022 6:00 pm